ABSTRACT
Objective To evaluate the relationship between smoking and p53 gene mutation in the lung cancer patients with Meta-analysis.Methods PubMed,Web of Science,ProQest and Medline were used to search all the relevant studies about the association between smoking and p53 gene mutation in the patients with lung cancer. Based on reviewing full text,the studies were selected and evaluated and the data was extracted.Statistical analysis was performed with Stata 1 2.0 software including the heterogeneity inspection, publication bias assessment, sensitivity analysis,effect consolidating and cumulative Meta-analysis.Results Totally 15 articles with 1 770 lung cancer patients were identified. 69.6% of the patients were smokers,30.4% were non-smokers.Overall,the smokers with lung cancer had a 2.70-fold higher risk for p53 gene mutation than the non-smokers with lung cancer (OR=2.70,95%CI=2.04-3.59).Conclusion p53 gene mutation is associated with smoking in the patients with lung cancer.The smokers with lung cancer have higher risk for p53 mutation than non-smokers.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the association between BRAF(V) 600E mutation and pathological features in papillary thyroid carcinoma (PTC).</p><p><b>METHODS</b>The raleted studies were searched through Medline, PubMed, and Web of Science, and meta-analysis was used to calculate the OR and 95%CI of the study results.</p><p><b>RESULTS</b>A total of 52 studies including 12 029 PTC patients was identified. The prevalence of BRAF(V) 600E mutation in PTC was 57.85%. There was a closed association between the BRAF(V) 600E mutation and pathological features, including advanced TNM stage (OR = 1.89, 95%CI 1.58-2.27), lymph node metastasis (OR = 1.74, 95%CI 1.42-2.14), multifocality (OR = 1.25, 95%CI 1.07-1.46), and recurrence (OR = 2.26, 95%CI 1.25-4.09) of PTC. For Asians with PTC, the association between the BRAF(V) 600E mutation and pathological features was indicated for advanced TNM stage (OR = 1.56, 95%CI 1.24-1.96) and lymph node metastasis (OR = 1.57, 95%CI 1.25-1.99). For Europeans with PTC, the association between the BRAF(V) 600E mutation and pathological features was indicated for advanced TNM stage (OR = 2.63, 95%CI 2.10-3.30), lymph node metastasis(OR = 1.97, 95%CI 1.19-3.25), and multifocality (OR = 1.35, 95%CI 1.01-1.80).</p><p><b>CONCLUSION</b>There were associations between the BRAF(V) 600E utation and advanced TNM stage, lymph node metastasis, multifocality, and recurrence of PTC.</p>
Subject(s)
Humans , Carcinoma , Diagnosis , Genetics , Pathology , Carcinoma, Papillary , Lymphatic Metastasis , Mutation , Neoplasm Recurrence, Local , Proto-Oncogene Proteins B-raf , Genetics , Thyroid Neoplasms , Diagnosis , Genetics , PathologyABSTRACT
OBJECTIVE:To discuss about the developmental strategy of Chinese pharmaceutical enterprises after entering WTO METHODS:To put forward the developmental strategy of Chinese pharmaceutical enterprises,through analyzing the present conditions of Chinese pharmaceutical enterprises and the facing challenges after entering WTO RESULTS & CONCLUSION:Chinese pharmaceutical enterprises can adopt integral strategy,attack strategy,brand strategy,scientific research innovation strategy to improve their market competitive ability